What is NRXS's market cap?

$86.15M, based on the Nov 4 close of $6.86.

Does Neuraxis pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NRXS is sold short?

412.8K shares, 4.8% of float, as of Oct 15, 2026.

What sector is NRXS in?

Healthcare, in the Electromedical Equipment industry.

NYSE American · NRXSHealthcareElectromedical Equipment

Neuraxis, Inc. (NRXS)

$6.86+4.26%

Close Nov 4, 2026 · split-adjusted

Oct 30, 2026$7.13▲ 166.04% in range

Nov 3, 2025Low $2.31 · High $8.81Oct 30, 2026

What changed · written from our data

As of Nov 4, 2026

Neuraxis closed at $6.86 on Nov 4, up 4.26%, 22.1% below its 52-week closing high. Volume of 98.2K shares was 0.65× its 20-day average (below normal).

Split-adjusted performance: +1.2% over one month, -22.1% over six months, +156.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.93M, up 115.7% from a year earlier, with a net margin of -118.1%.

Short interest was 412.8K shares at the Oct 15 settlement, up 10.7% from the prior report (4.8% of float, 2.3 days to cover).

Market cap$86.1M12.6M shares

Revenue · quarter$1.9M+115.7% YoY

Diluted EPS$-0.19—

P/E · TTM—P/S 16.2×

Net margin-118.1%Gross 85.9%

Dividend yieldNone

52-week range2.31 – 8.81−22.1% from high

Volume98.2K0.65× 20-day avg

Volatility · 60d70.3%Annualised

Short % of float4.8%2.3 days to cover

Net cash$8.3MCash $8.3M

Next earnings—Not scheduled

Split-adjusted performance

1W −9.4%1M +1.2%3M −1.0%6M −22.1%YTD +51.1%1Y +156.0%3Y +222.1%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Electromedical Equipment

Percentile among 22 companies (100 = best)

6-month momentum33

Revenue growth100

Net margin32

Value (low P/E)—

Size48

Industry medians: 6-month return −0.9%, revenue growth +13.9%, net margin −44.6%, P/E 23.7×.

Short interest

Details →

Shares short412.8K+10.7% vs prior

Days to cover2.3Settled Oct 15

% of float4.8%

Short vol. 10d49.7%of daily volume

Closest peers by size in Electromedical Equipment

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NRXSNeuraxis	$6.86	+4.26%	−22.1%	+115.7%	−118.1%	—	$86.1M
OMOutset Medical	$4.44	+6.99%	−1.6%	+0.7%	−56.8%	—	$83.5M	Compare
HYPRHyperfine	$0.7503	+8.36%	−56.6%	+44.8%	−238.2%	—	$79.6M	Compare
STXSStereotaxis	$0.9572	+13.55%	−50.1%	−12.8%	−62.3%	—	$95.9M	Compare
VANIVivani Medical, Inc. Common Stock (DE)	$1.07	+1.90%	−14.4%	—	—	—	$96.5M	Compare
ECORelectroCore	$8.40	+16.18%	+26.1%	+28.0%	−32.4%	—	$75.7M	Compare
POCIPrecision Optics	$4.84	+3.42%	+2.8%	+42.0%	−1.2%	—	$53.2M	Compare
STEXStreamex	$0.3610	−5.00%	−64.3%	—	−9968.5%	—	$42.0M	Compare
QTIQT Imaging Holdings	$2.19	+1.39%	−69.2%	+103.2%	−148.9%	—	$32.1M	Compare

News about Neuraxis

All news →

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026GlobeNewswire Inc. · May 5, 2026Neutral

Quick answers

What does Neuraxis do?: Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
What is NRXS's market cap?: $86.15M, based on the Nov 4 close of $6.86.
Does Neuraxis pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NRXS is sold short?: 412.8K shares, 4.8% of float, as of Oct 15, 2026.
What sector is NRXS in?: Healthcare, in the Electromedical Equipment industry.

About Neuraxis

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

HQ: Carmel, IN24 employeesListed Aug 9, 2023neuraxis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology